Mineralys Therapeutics (MLYS) Soars 41.8% on Institutional Investments

Mineralys Therapeutics, Inc. (MLYS) shares surged 41.8% in pre-market trading on September 2, 2025, driven by significant institutional investments and strategic moves.

Wellington Management Group LLP and Charles Schwab Investment Management Inc. have both increased their positions in Mineralys Therapeutics, indicating strong confidence in the company's future prospects. These institutional investments suggest that Mineralys is poised for growth, potentially attracting more investors and driving further stock price appreciation.

Russell Investments Group Ltd. has also shown interest in Mineralys, boosting its holdings in the company. This move by a major investment firm further validates the positive outlook for Mineralys Therapeutics, as institutional investors typically conduct thorough research before making significant investments.